Sign In
Buy AGEN
$3.07
+0.0300 (+0.99%)
At Close: Jun 23, 2026
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
03:30pm, Thursday, 30'th May 2024
Human life expectancy has doubled since the 1900s, mostly attributed to advancements in lifestyle, living standards and medicine. Thanks to biotech companies that produce transformative drugs and trea
7 Biotech Stocks to Put on Your Breakthrough Radar
12:32pm, Monday, 27'th May 2024
For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let's get some of the bad stuff out of the way fir
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Friday, 24'th May 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compe
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
05:10pm, Thursday, 23'rd May 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced a novel analysis from the Phas
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
07:30am, Thursday, 23'rd May 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo
3 Magnificent Growth Stocks to Buy Hand Over Fist
07:30am, Wednesday, 22'nd May 2024
Small- and mid-cap stocks are known to be highly sensitive to interest rates. With the Federal Reserve expected to start cutting rates no later than 2025, these equities may be on the verge of a turna
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
07:30am, Thursday, 16'th May 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced it will conduc
Agenus Inc. (AGEN) Q1 2024 Earnings Call Transcript
01:45pm, Tuesday, 07'th May 2024
Agenus Inc. (NASDAQ:AGEN ) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Zack Armen - Head of Investor Relations Garo Armen - Chairman & Chief Executive Officer Steven O
Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates
10:01am, Tuesday, 07'th May 2024
Agenus (AGEN) came out with a quarterly loss of $3.04 per share versus the Zacks Consensus Estimate of a loss of $3.58. This compares to loss of $4.40 per share a year ago.
Agenus Reports First Quarter 2024 Results
07:40am, Tuesday, 07'th May 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced results for th
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
07:30am, Tuesday, 07'th May 2024
JUPITER, Fla. and LEXINGTON, Mass.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) and Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agent
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
07:30am, Wednesday, 01'st May 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immunology-based therapies for cancer, received notice from NASDAQ on April 30, 2024, that the Company has reg
Up 40%: Is This Red-Hot Growth Stock Still a Buy?
08:30am, Sunday, 28'th Apr 2024
Agenus, a small-cap immunotherapy company, notched a 40% gain last Friday. Investors appear to be bidding up the stock ahead of first-quarter earnings on May 7.
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
10:00am, Wednesday, 24'th Apr 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced an upcoming presentation from
Top 2 Health Care Stocks Which Could Rescue Your Portfolio This Month - Agenus (NASDAQ:AGEN), MultiPlan (NYSE:MPLN)
08:36am, Tuesday, 23'rd Apr 2024
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
